Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:CNABOTCMKTS:PKPHOTCMKTS:PVSPNASDAQ:XXII On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCNABUnited Cannabis$0.00$0.02▼$0.78$1.55MN/A730,433 shs7.53 million shsPKPHPeak Pharmaceuticals$1.02-11.3%$3.46$0.52▼$9.12$400K0.549,053 shs2,745 shsPVSPPervasip$0.00+50.0%$0.00$0.00▼$0.00$1.63M-0.473.70 million shs2.00 million shsXXII22nd Century Group$0.75-2.8%$1.02$0.70▼$140.40$1.78M1.95440,847 shs143,960 shs12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCNABUnited Cannabis0.00%0.00%0.00%0.00%0.00%PKPHPeak Pharmaceuticals-11.30%-32.00%-71.67%-85.43%-74.50%PVSPPervasip0.00%0.00%0.00%+50.00%0.00%XXII22nd Century Group0.00%-14.19%-16.29%-60.76%-99.55%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCNABUnited CannabisN/AN/AN/AN/AN/AN/AN/AN/APKPHPeak PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/APVSPPervasipN/AN/AN/AN/AN/AN/AN/AN/AXXII22nd Century Group0.3388 of 5 stars0.04.00.00.01.80.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCNABUnited Cannabis 0.00N/AN/AN/APKPHPeak Pharmaceuticals 0.00N/AN/AN/APVSPPervasip 0.00N/AN/AN/AXXII22nd Century Group 0.00N/AN/AN/ALatest PKPH, XXII, PVSP, and CNAB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/24/2025XXII22nd Century GroupWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E) ➝ Sell (E+)5/10/2025XXII22nd Century GroupWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (E)4/24/2025XXII22nd Century GroupWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E) ➝ Sell (E+)4/8/2025XXII22nd Century GroupWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (E)3/22/2025XXII22nd Century GroupWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E) ➝ Sell (E+)3/7/2025XXII22nd Century GroupWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (E)(Data available from 6/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCNABUnited CannabisN/AN/AN/AN/AN/AN/APKPHPeak PharmaceuticalsN/AN/AN/AN/AN/AN/APVSPPervasip$15.77M0.10N/AN/AN/A∞XXII22nd Century Group$11.07M0.16N/AN/A($417.78) per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCNABUnited CannabisN/AN/A0.00N/AN/AN/AN/AN/AN/APKPHPeak Pharmaceuticals-$160KN/A0.00∞N/AN/AN/A-159.55%N/APVSPPervasip-$2.35MN/A0.00∞N/A-16.98%N/A-21.52%N/AXXII22nd Century Group-$140.77M-$2,986.49N/A∞N/A-144.09%N/A-130.16%8/12/2025 (Estimated)Latest PKPH, XXII, PVSP, and CNAB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025XXII22nd Century Group-$1.10-$1.89-$0.79-$2.50$4.70 million$5.96 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCNABUnited CannabisN/AN/AN/AN/AN/APKPHPeak PharmaceuticalsN/AN/AN/AN/AN/APVSPPervasipN/AN/AN/AN/AN/AXXII22nd Century GroupN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCNABUnited CannabisN/AN/AN/APKPHPeak PharmaceuticalsN/A0.150.15PVSPPervasipN/A0.190.05XXII22nd Century Group1.591.090.93Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCNABUnited CannabisN/APKPHPeak PharmaceuticalsN/APVSPPervasipN/AXXII22nd Century Group18.06%Insider OwnershipCompanyInsider OwnershipCNABUnited CannabisN/APKPHPeak Pharmaceuticals18.40%PVSPPervasip9.20%XXII22nd Century Group0.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCNABUnited Cannabis6593.73 millionN/ANot OptionablePKPHPeak Pharmaceuticals1392,000320,000Not OptionablePVSPPervasip35.43 billion4.93 billionNot OptionableXXII22nd Century Group802.36 million1.72 millionOptionablePKPH, XXII, PVSP, and CNAB HeadlinesRecent News About These Companies22nd Century Group, Inc. (NASDAQ:XXII) Sees Significant Drop in Short InterestMay 30 at 1:27 AM | americanbankingnews.com22nd Century limits fiscal 2024 executive compensation, proposes another reverse stock splitMay 27, 2025 | journalnow.com22nd Century Group (NASDAQ:XXII) Receives Sell (E+) Rating from Weiss RatingsMay 27, 2025 | americanbankingnews.com22nd Century Group (NASDAQ:XXII) Earns "Sell (E+)" Rating from Weiss RatingsMay 27, 2025 | americanbankingnews.com22nd Century Group's (XXII) Sell (E+) Rating Reaffirmed at Weiss RatingsMay 27, 2025 | americanbankingnews.com22nd Century Group (NASDAQ:XXII) Downgraded to "Sell" Rating by Wall Street ZenMay 23, 2025 | americanbankingnews.comEmerging Growth Research Releases Q1 2025 Update Report on 22nd Century GroupMay 21, 2025 | newsfilecorp.com22nd Century to Present at the Emerging Growth Conference on May 21, 2025May 19, 2025 | globenewswire.com22nd Century Group, Inc. (NASDAQ:XXII) Q1 2025 Earnings Call TranscriptMay 15, 2025 | msn.com22nd Century: Q1 Earnings SnapshotMay 14, 2025 | wtop.com22nd Century reports lower quarterly loss, still no net revenue from very-low-nicotine cigarettesMay 14, 2025 | journalnow.com22nd Century Group Inc (XXII) Q1 2025 Earnings Call Highlights: Revenue Surge and Strategic ...May 14, 2025 | finance.yahoo.com22nd Century Group, Inc. (XXII) Q1 2025 Earnings Call TranscriptMay 13, 2025 | seekingalpha.com22nd Century Group Reports First Quarter 2025 Financial ResultsMay 13, 2025 | globenewswire.com22nd Century Group, Inc.: 22nd Century Group Completes Sale of Needle Rock Farms AssetsMay 9, 2025 | finanznachrichten.de22nd Century Group, Inc. Reports $1 Million Debt Repayment, Achieving $3.8 Million Year-to-Date ReductionMay 9, 2025 | nasdaq.com22nd Century Group, Inc. Enhances Balance Sheet with $770,000 Asset Sale ProceedsMay 8, 2025 | quiverquant.com22nd Century Group Completes Sale of Needle Rock Farms AssetsMay 8, 2025 | globenewswire.com22nd Century Group, Inc.: 22nd Century Group Further Reduces Debt by $1.0 Million Following Financing TransactionMay 8, 2025 | finanznachrichten.de22nd Century Group Further Reduces Debt by $1.0 Million Following Financing TransactionMay 7, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePKPH, XXII, PVSP, and CNAB Company DescriptionsUnited Cannabis OTCMKTS:CNABUnited Cannabis Corporation owns intellectual properties related to growth, production, manufacture, marketing, management, utilization, and distribution of medical marijuana and marijuana infused products in the United States. The company focuses on developing therapeutics, including Prana Bio Nutrient Medicinal products for supplement deficiencies related to the endocannabinoid system, including pain, neuropathy, arthritis, MS, IBS, autism, seizures, eczema, sleep, anxiety, head trauma, opioid dependency, and clinical endocannabinoid deficiencies; and Prana Aromatherapy Transdermal Roll-on line that provides targeted and large surface relief with combinations of aromatherapy. The company was formerly known as MySkin, Inc. and changed its name to United Cannabis Corporation in May 2014. United Cannabis Corporation was founded in 2007 and is based in Golden, Colorado.Peak Pharmaceuticals OTCMKTS:PKPH$1.02 -0.13 (-11.30%) As of 05/30/2025Peak Pharmaceuticals, Inc. manufactures and markets pharmaceutical level products containing phytocannabinoids, an abundant and pharmaceutically active component of industrial hemp for the prevention and alleviation of various conditions and diseases. The company was founded on December 18, 2007 and is headquartered in Scottsdale, AZ.Pervasip OTCMKTS:PVSP$0.0003 +0.00 (+50.00%) As of 05/30/2025 10:29 AM EasternPervasip Corporation focuses on developing cloud-based applications to monitor and control greenhouse facilities. It intends to develop and deliver products and technologies to agricultural markets; develop scientific methods for the analysis of cannabinoids in flowers, concentrates, and edibles; and assist medical marijuana specialty production facilities to regulate, calculate proper dosage, and understand the importance of consistency in product. The company was formerly known as eLEC Communications Corp. and changed its name to Pervasip Corp. in December 2007. Pervasip Corp. was founded in 1964 and is based in White Plains, New York.22nd Century Group NASDAQ:XXII$0.75 -0.02 (-2.76%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$0.77 +0.02 (+2.34%) As of 05/30/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.22nd Century Group, Inc., a tobacco products company, engages in the sale and distribution of its own proprietary new reduced nicotine tobacco products. The company offers reduced nicotine content tobacco plants and very low nicotine combustible cigarette products. It also provides contract manufacturing services for conventional combustible tobacco products for third-party brands. The company was founded in 1998 and is headquartered in Mocksville, North Carolina. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/26 - 05/30 Super Micro Computer Stock Finding Upside With NVIDIA's Blackwell Ackman Takes a Swing at Amazon — Should You? Taiwan Semiconductor: Time to Buy After Strong NVIDIA Results? Intel’s Turnaround May Be the Best Bet No One’s Watching Nike’s Amazon Expansion Could Signal a Turnaround in 2025 ASML Stock Might Be the Safest Chip Play at This Price Archer Aviation Stock Steadies After Short-Seller Report Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
